Project Grant R01HL174866
Award Date
8/1/25
Completion Date
5/31/30
Dollars Obligated
$695K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Missouri, USA
Similar Awards
This Project Grant awarded by the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $776,791 to The Washington University, located in Missouri, to investigate the impact of sequence changes on key intrinsically disordered regions of cardiac troponin. The research aims to connect how changes in sequence affect the structure, function, and interactions of the troponin complex, which plays a central role in regulating cardiac muscle contraction. The...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $663,578 to the University of Washington to conduct research on inflammatory and genetic cardiomyopathies. The key objectives are to: 1) help clinicians determine when to order genetic testing and positron emission tomography (PET) scans, 2) develop minimally invasive diagnostic tests to identify the mechanism behind "idiopathic...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $135,840 to the University of Washington from September 1, 2024 to August 31, 2026. The project will investigate the mechanisms of cardiac contractile dysfunction across multiple scales using a combined computational and experimental platform. Specifically, the work will focus on how structural perturbations to the myosin protein affect its...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research (CFDA 93.837) program supports research into the regulation of the autophagy pathway and its relationship to cardiomyopathy and heart failure. The $2,185,454 award to Tufts Medical Center Parent, Inc. will fund a 4-year study investigating the mechanistic basis of a genetic variant (FHOD3V1151I) associated with hypertrophic cardiomyopathy. Key objectives...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $126,306 Project Grant under CFDA 93.837 - Cardiovascular Diseases Research to the University of Washington. The goal of this 2-year award is to establish a system to accelerate the reclassification of variants of unknown significance in the MYH7 gene, which cause hypertrophic cardiomyopathy, and determine the role of genetic modifiers that influence the severity of this disease. The research will utilize human induced pluripotent...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research federal grant program (CFDA 93.837), provides $116,250.00 to the Regents of the University of Minnesota to conduct research on identifying the underlying causes of cardiomyopathy. The research aims to evaluate the use of cardiac magnetic resonance imaging to reclassify the causes of cardiomyopathy, which could lead to more accurate diagnosis and appropriate...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $817,208 to The Broad Institute, Inc. to investigate the genetic basis and underlying mechanisms of heart failure. The research leverages high-throughput cellular analysis techniques, including cell painting and Perturb-seq, to functionally characterize genetic variants associated with heart failure risk. The goal is to rapidly...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $498,991.40 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the University of Arkansas. The grant, effective January 2, 2025 through December 31, 2027, will support the development of microphysiological systems to investigate molecular pathways and cardiomyocyte function in response to hypoxic cardiac injury associated with myocardial infarction and ischemia-reperfusion injury. The project aims to...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $711,039 to the Research Institute at Nationwide Children's Hospital to conduct research on the role of cardiac m6A methyltransferases in the pathogenesis of fetal dilated cardiomyopathy (DCM). The key objectives are to determine the functions of the m6A methyltransferases METTL3 and METTL14 in embryonic mouse myocardium and whether their...
This Project Grant award of $601,563 was provided by the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research federal grant program (CFDA 93.837), with a project period from September 1, 2024 to August 31, 2027. The award supports research to investigate the pathogenic roles and molecular mechanisms of the histone lysine demethylases KDM5A and KDM5B in the development and progression of heart failure, with a focus on hereditary cardiomyopathies like Lamin...